A Breakthrough in Stroke Science

PSE.SR.screenshot  PSE.SR.p3 

Learn more. For the lay reader, watching or reading the media stories (click here for partial list) may be the most accessible way to begin to understand the promise of this scientific approach. For those with scientific training, please read INR published scientific articles (article 1article 2; article 3). Please read news stories (article 1, article 2) about others that have been helped by INR physicians.

For more information, or to schedule an appointment for screening or consultation, please call the INR in California directly at (310) 479-0107 or in Florida at (561) 353-9707.

INR physicians are pleased to make this therapeutic approach available for selected patients. Individual results vary, not all patients respond. Treatment is an innovative off-label patented invention of the INR®. Additional doses may be needed for optimal benefit, please see the Terms of Use. These unprecedented clinical results rely upon the Institute’s patented TransBarrier® drug delivery methodology, covered by multiple issued and pending U.S. and international patents, including U.S. patents 6419944, 6537549, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, assigned to TACT IP, LLC and Australian patent 758,523. See the following published, peer-reviewed articles: